Androgen ablation therapy, using luteinizing hormone-releasing hormone agonists (LH-RH) (also known as gonadotropin-releasing hormone, GnRH) or bilateral orchiectomy, has become a primary treatment for metastatic prostate cancer [6]. The gene discussed is GNRH1; the disease is metastatic prostate carcinoma.